NEW YORK – Analytics firm Definitive Healthcare has gained a foothold in the genomics market by acquiring PatientFinder, a cohort-building company serving the life sciences market. Terms of the deal were not disclosed.
The acquisition closed in December, but Framingham, Massachusetts-based Definitive Healthcare did not announce the transaction until Monday.
PatientFinder, headquartered in Plantation, Florida, makes technology to help life sciences companies and healthcare providers identify groups of patients who might benefit from various drugs, medical devices, and services.
With the acquisition, PatientFinder's technology has been separated into two distinct brand names, according to Dave Thornton, ex-CEO of Patient Finder who now serves as senior vice president of innovation for Definitive Healthcare.
The PatientFinder name survives as a sales and marketing tool for pharma and medical device sales representatives, Thornton said. PatientFinder has rebranded the research and treatment side of the business as CohortBuilder.
CohortBuilder analyzes diagnosis and treatment history from medical claims data — including genetic markers — to help clinicians better care for individuals and patient populations.
A Definitive Healthcare spokeswoman told GenomeWeb via email that this technology allows clients to assemble "cohorts of patients whose medical history suggests they’d be good candidates for formal diagnosis," something that is especially useful for clinical trials.
In the longer term, the newly expanded Definitive Healthcare is looking to create its own genomic data pipeline that it would deliver through CohortBuilder, the spokeswoman said.
"With [this] acquisition of PatientFinder, Definitive accelerates progress against its strategic roadmap – to provide end-to-end, go-to-market solutions that bridge the gap between data and action," Definitive Healthcare Founder and CEO Jason Krantz said in a statement. "It's demonstrative of our commitment to enabling client growth by integrating patient and provider insights directly into our clients' existing processes for strategic analytics, go-to-market planning, and field execution."